The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rheumatologists Concerned High Healthcare Costs May Encourage Patients to Forgo, Delay Treatment

Rheumatologists Concerned High Healthcare Costs May Encourage Patients to Forgo, Delay Treatment

June 14, 2017 • By Susan Bernstein

  • Tweet
  • Email
Print-Friendly Version / Save PDF

High-deductible plans, which require policyholders to pay out of pocket up to a coverage limit for their drugs or other costs of care, seem to be on the rise too. According to a survey by the Henry J. Kaiser Family Foundation in 2016, 29% of covered workers were enrolled in a high-deductible health plan in the U.S., up from 24% the year before.2 Medicare beneficiaries may incur high out-of-pocket costs for biosimilars based on current regulatory manufacturer brand discount program requirements if they are in the coverage gap phase of their Medicare Part D prescription drug benefit and have not entered the catastrophic benefit phase, says Ms. Arquette.

You Might Also Like
  • High Cost of DMARDs Could Limit Medicare Patients’ Treatment Adherence
  • FDA’s Gottlieb Blames Industry ‘Kabuki Drug Pricing’ for High Costs
  • Rising Costs of Biologics in the U.S. Suggest Need for Negotiation Ability
Explore This Issue
June 2017
Also By This Author
  • Research Reveals Clues Into Inflammatory Process of Crystal Arthropathies Note Experts at the 2013 ACR/ARHP Annual Meeting

Some patients may try to switch to a biosimilar for possible cost savings, says Ms. Arquette, but “if a patient has been on a drug like infliximab, one of the first biologics, for a long time, and has had active disease that has gone into remission, does the physician want to risk how this patient is doing? Would switching really be that effective?” she says. “You have to consider the total cost of care. If you increase overall medical costs, where are the real savings?”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Some rheumatologists are optimistic about the cost-saving potential for biosimilars, although regulatory problems still need to be worked out. Spiking biologic prices makes the successful acclimation of biosimilars to the marketplace an urgent priority, says Angus B. Worthing, MD, FACP, a rheumatologist at Arthritis and Rheumatism Associates in Washington, D.C., and chair of the ACR’s Government Affairs Committee.

“From 2010, when Congress authorized the FDA to approve biosimilars, to 2016, the price of infliximab (Remicade) increased 70%. The first biosimilar in rheumatology, Inflectra, a biosimilar to Remicade, launched at just a 15% discount to Remicade,” he says. “Similar price hikes prior to patent expiration are common for small-molecule [drugs] before generics compete to drive prices back down. In contrast to generic pricing, biosimilars are not expected to drive prices down quickly. Indeed, at this time of large biologic price hikes and subtle biosimilars discounts, it seems the biosimilar marketplace has cost the U.S. a lot of money, and it will take multiple biosimilars per reference product, or maybe the emergence of interchangeable biosimilars, to compete enough to lower the price significantly.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Interchangeables are biologic products that are expected to produce the same clinical result as the reference drug in any given patient, according to the FDA. No drug manufacturer has applied for this status yet.

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Practice Management Tagged With: Biologics, biosimilar, Compliance, cost, drug, generic, Healthcare, Medication, patient care, Rheumatic Disease, rheumatologist, TreatmentIssue: June 2017

You Might Also Like:
  • High Cost of DMARDs Could Limit Medicare Patients’ Treatment Adherence
  • FDA’s Gottlieb Blames Industry ‘Kabuki Drug Pricing’ for High Costs
  • Rising Costs of Biologics in the U.S. Suggest Need for Negotiation Ability
  • 8 Ways to Help Your Patients with Medication Costs

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.